September 21, 2022
Earlier this month Biocase secured a licence from the Brazilian Ministry of Education, to train psychedelic-assisted therapists at Alma Viva
September 14, 2022
Double-blind randomised clinical trials A double-blind randomised clinical trial prevents bias when evaluating patient outcomes, validating the research. It is
September 7, 2022
PSYCH spoke with Angela Allbee, Oregon Psilocybin Services Section Manager at Oregon Health Authority, for The Psychedelics as Medicine Report:
August 31, 2022
In July, Ann Shulgin passed away following a long battle with lung disease. Alongside late husband Alexander Shulgin, Ann detailed
August 24, 2022
Earlier this month, the Thai government announced it will develop depression treatments from psilocybin-producing fungi. The World Health Organization estimates
August 17, 2022
In July, UK-based COMPASS Pathways’ share price surged 40% – far outpacing the market’s rebound. Notable inflection points included the
August 10, 2022
The World Health Organization recently released its mental health report, which analysed the scale of the mental health crisis and
August 2, 2022
Last week, the U.S Department of Health and Human Services revealed the government expects both MDMA and psilocybin to be
July 27, 2022
There are strong signs Europe and North America are about to enter a recession, as sanctions against Russian oil and
July 20, 2022
Britain’s burgeoning psychedelic healthcare ecosystem includes leading research institutions, drug developers and clinical operations, with ancillary organisations providing essential financial
July 13, 2022
On Monday, over 100 healthcare professionals in Canada challenged the health minister’s decision to reject their application to access psilocybin.
July 6, 2022
Access to therapists is critical to the adoption of psychedelic-assisted therapy, and ensuring market access is crucial for the industry
